Literature DB >> 8849262

Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

S Merali1, A B Clarkson.   

Abstract

Difluoromethylornithine (DFMO; eflornithine hydrochloride [Ornidyl]), a suicide inhibitor of the key polyamine biosynthesis enzyme ornithine decarboxylase (ODC), is effective in treating Pneumocystis carinii pneumonia, a common opportunistic infection associated with AIDS. Despite DFMO's specificity for ODC, the reason for its selective toxicity against P. carinii is unknown since both host and parasite are dependent on the same enzyme for polyamine biosynthesis. A new high-performance liquid chromatography method was used with P. carinii cells isolated from infected rat lungs to measure polyamine content, to confirm the presence of ODC, and to examine the effect of DFMO on polyamine concentrations. Putrescine, spermidine, and spermine were found to be present at 2.00 +/- 0.54, 1.26 +/- 0.51, and 1.59 +/- 0.91 nmol (mg of protein)-1, respectively, neither unusually high nor low values. ODC's specific activity was 79 +/- 11 pmol (mg of protein)-1 h-1, again not a remarkable value. However, the rates of both DFMO-induced polyamine depletion and subsequent repletion upon DFMO removal were unusually high. A 3-h exposure to 1 mM DFMO in vitro caused the depletion of putrescine, spermidine, and spermine to levels 12, 29, and 16%, respectively, of that of control cells. After DFMO removal and incubation for 1 h in serum-free media, polyamine levels returned to 78, 88, and 64%, respectively, of that of the control cells not exposed to DFMO. Since such depletions and repletions usually occur over periods of days rather than hours, these rapid changes may provide a clue to the selective action of DFMO against P. carinii and may guide the development of new compounds and an optimal drug administration schedule for DFMO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849262      PMCID: PMC163241     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

Review 1.  Polyamines.

Authors:  C W Tabor; H Tabor
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

Review 2.  Chemotherapeutic implications of polyamine biosynthesis inhibition.

Authors:  A Sjoerdsma; P J Schechter
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

3.  Polyamine analysis using N-hydroxysuccinimidyl-6-aminoquinoyl carbamate for pre-column derivatization.

Authors:  S Merali; A B Clarkson
Journal:  J Chromatogr B Biomed Appl       Date:  1996-01-26

4.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

5.  Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome.

Authors:  J A Golden; A Sjoerdsma; D V Santi
Journal:  West J Med       Date:  1984-11

Review 6.  Polyamine metabolism and function.

Authors:  A E Pegg; P P McCann
Journal:  Am J Physiol       Date:  1982-11

7.  Effect of methylglyoxal bis(guanylhydrazone) on polyamine metabolism in normal and regenerating rat liver and rat thymus.

Authors:  E Hölttä; P Hannonen; J Pispa; J Jänne
Journal:  Biochem J       Date:  1973-11       Impact factor: 3.857

8.  Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis.

Authors:  A J Bitonti; C J Bacchi; P P McCann; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1985-05-15       Impact factor: 5.858

9.  Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Effect of inhibition of polyamine synthesis on the content of decarboxylated S-adenosylmethionine.

Authors:  A E Pegg; H Pösö; K Shuttleworth; R A Bennett
Journal:  Biochem J       Date:  1982-02-15       Impact factor: 3.857

View more
  9 in total

1.  Effect of a bis-benzyl polyamine analogue on Pneumocystis carinii.

Authors:  S Merali; M Saric; K Chin; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  Thymopoietic and bone marrow response to murine Pneumocystis pneumonia.

Authors:  Xin Shi; Ping Zhang; Gregory D Sempowski; Judd E Shellito
Journal:  Infect Immun       Date:  2011-02-22       Impact factor: 3.441

4.  Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.

Authors:  K Chin; S Merali; M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Continuous axenic cultivation of Pneumocystis carinii.

Authors:  S Merali; U Frevert; J H Williams; K Chin; R Bryan; A B Clarkson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  Development and evaluation of a molecular viability assay for Pneumocystis carinii.

Authors:  N Maher; S Vermund; M Lasbury; C Lee; M Bartlett; T R Unnasch
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

7.  Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.

Authors:  M S Bartlett; W C Angus; M M Shaw; P J Durant; C H Lee; J M Pascale; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

8.  Action of deferoxamine against Pneumocystis carinii.

Authors:  A B Clarkson; D Turkel-Parrella; J H Williams; L C Chen; T Gordon; S Merali
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Intranasal immunization confers protection against murine Pneumocystis carinii lung infection.

Authors:  J M Pascale; M M Shaw; P J Durant; A A Amador; M S Bartlett; J W Smith; R L Gregory; G L McLaughlin
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.